Cipla Ltd. on Friday said the U.S. District Court of Delaware has denied Amgen Inc's request for preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets in the U.S. market.
Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order to preserve the status quo until the trial is over and the court has issued a ruling or judgment.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Cipla had announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, in the U.S. market in a regulatory filing in March this year. The launch, however, is a subject of ongoing litigation, it had added.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
"... Chief Judge Stark of the U.S. District Court of Delaware denied Amgen Inc's request for preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets 30 mg, 60 mg, 90 mg in the U.S.A.," Cipla said in a filing to Bombay Stock Exchange.
Cipla's cinacalcet hydrochloride tablets in the strengths of 30 mg, 60 mg and 90 mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
